Medications for Opioid Use Disorder: A Comparison

Which medications treat opioid use disorder?

Buprenorphine, methadone, and naltrexone are approved to treat opioid use disorder. Buprenorphine and methadone activate opioid receptors in controlled ways to reduce withdrawal and craving. Naltrexone blocks opioid effects after an opioid-free period. All three can be part of a broader plan that includes behavioral, medical, psychiatric, family, and practical support.

Medication choice is not a moral ranking. Access, prior response, current opioid exposure, pregnancy, pain, other medicines, health conditions, treatment goals, and personal preference can all matter. See FDA information about MOUD.

What is buprenorphine's role in opioid addiction treatment?

Buprenorphine is a partial opioid agonist used to treat opioid use disorder. Qualified clinicians prescribe its different formulations in authorized office-based and other settings, with monitoring and continuing access.

The starting process must be clinically managed because timing matters and precipitated withdrawal can occur. Ongoing comparison questions include prescriber access, pharmacy supply, visit frequency, formulation, urine or other monitoring, travel, pain care, and what happens after missed doses or resumed use.

The pharmacy and next visit belong on the same calendar as behavioral appointments.

How is methadone accessed for opioid use disorder?

Methadone is a full opioid agonist used to reduce withdrawal and craving and support treatment stability. In the United States, methadone for opioid use disorder is dispensed through certified opioid treatment programs. Program attendance, take-home medication, counseling, testing, and other requirements can change over time and by individual plan.

A program that cannot dispense methadone may still be able to coordinate transportation and continuity with an opioid treatment program.

Travel plans need coordination with that medication service before the person changes location.

What that looks like day to day: intake at a certified opioid treatment program, then supervised visits and take-home arrangements set by the program according to clinical needs and applicable rules. Federal rules allow take-home doses early in treatment when the treating practitioner determines they are appropriate. Methadone is a full opioid agonist, which is why it is dispensed this way, and also why it works well for people with heavy fentanyl use who struggle to start buprenorphine. A residential or one-client program that cannot dispense it can still support it by coordinating the required visits, transport, and medication access with the opioid treatment program, and should say so plainly.

How does naltrexone differ from buprenorphine and methadone?

Naltrexone is an opioid antagonist that blocks opioid effects and can reduce cravings. It is available in oral and extended-release injectable forms. Unlike buprenorphine and methadone, it does not activate opioid receptors, but it requires a sufficient opioid-free interval before starting, with the timing set by the prescriber from the opioids used and the person's condition. That requirement can make initiation difficult for some people. Discuss the formulation, adherence, and the overdose risk if treatment stops or opioid use returns.

The appointment schedule also differs between daily oral medication and a long-acting injection. The prescriber reviews the formulation, expected visits, other medicines, and follow-up. A person changing programs needs those details documented so the receiving provider understands the current plan.

How do buprenorphine, methadone, and naltrexone compare?

These are questions a prescriber works through with you, not a self-assessment. How heavy is the opioid use, and is fentanyl involved? Methadone and buprenorphine are options; fentanyl use makes an individualized starting plan especially important. Can the person attend an opioid treatment program as often as required? Buprenorphine may instead be available through an authorized prescriber and pharmacy, with an injectable option for some people. Does the person prefer a non-opioid medication? Naltrexone requires an opioid-free period before starting; any work restriction needs to be clarified rather than assumed. Is there a prior history with one of the medicines? What helped, what did not, and why treatment stopped can inform the next choice. Buprenorphine and methadone reduce deaths; naltrexone's evidence on mortality is weaker. Reduced tolerance raises overdose risk if opioid use returns, including after naltrexone stops. SAMHSA's TIP 63 is the reference clinicians use.

This table is educational and excludes dosing, individualized timing, and medication recommendations. A medical prescriber must make those decisions.

Swipe sideways to see all columns.

Does MOUD replace behavioral treatment or recovery support?

No, and it also does not require it as a condition. Federal guidance is that medication should not be withheld because a person declines counseling; the medication works on its own to reduce use and deaths, and therapy adds to it. The right framing is medication first, therapy alongside, and support around both.

Medication addresses core opioid use disorder symptoms. Behavioral care addresses goals such as coping, relationships, routines, and mental health. The required amount differs by patient, and counseling barriers must not prevent appropriate medication access.

Individual delivery preserves privacy while maintaining necessary medication and medical care.

For example, a medication visit might focus on response and access, while a therapy session works through a difficult relationship or a recurring trigger. Scheduling both according to need gives each service a clear role in the person's recovery plan.

Is MOUD replacing one opioid with another?

No. Methadone and buprenorphine are evidence-based medications provided in a controlled treatment context to reduce withdrawal, craving, illicit opioid use, and overdose risk. Their opioid-receptor activity is part of how they treat the disorder. Naltrexone works differently by blocking opioid effects after an opioid-free interval.

The more useful question is whether the medication is medically appropriate, accessible, effective for the person, and supported over time. Treatment quality should be judged by informed consent, clinical monitoring, retention, safety, functioning, and continuity rather than whether a program follows an abstinence-only philosophy about medication.

How private care delivers the treatment

A private program delivers or coordinates prescribing, medication access, monitoring, and behavioral appointments. Responsibility remains with the treating clinicians and authorized medication providers. Medication access requires a prescribing or dispensing arrangement with the appropriate clinical service.

For a residential stay, the plan identifies whether the prescriber visits, sees the person remotely, or works from an outside office. Transport and pharmacy arrangements then follow. Before departure, the next medication appointment is booked and the receiving service receives the relevant treatment information, keeping the medication plan connected across a change of setting.

For buprenorphine, private delivery can involve an authorized physician or nurse practitioner who bills directly, visits by telehealth where permitted, and a pharmacy. Monthly buprenorphine or naltrexone injections need a practice equipped to supply and administer them. Methadone treatment for opioid use disorder is generally accessed through a certified opioid treatment program, which may itself be privately operated or accept private payment. A separate private program may help coordinate appointments and transport.

What should you ask before choosing a medication plan?

Medication planning covers the clinical reason for the choice, safe initiation, other medicines, follow-up, practical access, and continuity. The prescriber explains precautions and changes.

Which options are medically reasonable for me?

Review current opioid exposure, other substances, health, pregnancy, pain, medicines, prior response, and preferences.

How will treatment begin safely?

Ask the clinician to explain evaluation, timing, monitoring, and what to do if problems occur.

Can I access the medication reliably?

Confirm prescriber, pharmacy or opioid treatment program, appointments, transportation, payment, and supply.

What happens after resumed use or missed care?

Look for rapid reassessment, overdose prevention, medication continuity, and re-engagement.

How will treatment continue during travel or a program change?

Confirm records, releases, prescriptions, take-home arrangements, transfer acceptance, and next appointments.

Opioid medication access and follow-up

A complete handoff records the current medicine, the responsible service, and the next appointment. The patient also needs the location, transport plan, and a reliable contact for scheduling problems.

How would an existing medication plan continue?

Before a move to any program, the current prescriber and the receiving service confirm in writing: the medication and dose, who prescribes during the stay, where it is dispensed, and the supply that covers travel days. For methadone, confirm with the opioid treatment program whether continuity will use authorized take-home doses, guest dosing, or transport for required visits. A person should never travel to a program that has not confirmed continuity.

Who provides prescribing and follow-up?

A named prescriber (physician, nurse practitioner, or physician assistant) or a named opioid treatment program, with follow-up set for the medication, formulation, clinical needs, and take-home arrangements. Buprenorphine injections may be weekly or monthly; extended-release naltrexone is monthly. A residential program without a prescriber on its team should name the outside one it uses.

What happens to medication access when I leave?

Medication in hand at discharge, a prescriber who has already agreed to continue, the first appointment booked within a week, and a pharmacy that will fill it. The end of a stay is not the end of medication; stopping is a separate decision made with the prescriber months or years later.

US access rules

The federal X-waiver requirement for prescribing buprenorphine for opioid use disorder has been removed. Prescribing still requires appropriate DEA registration, professional authority, and compliance with applicable rules. The removal does not mean every clinician offers treatment. These rules were last checked on September 7, 2026; recheck them before relying on them.

Routine outpatient methadone treatment for opioid use disorder is provided through federally certified opioid treatment programs, subject to applicable rules and limited exceptions in other medical settings. A private residence does not become an opioid treatment program by arranging individual therapy.

Common questions about medications for opioid use disorder

Sources and further reading

• FDA: Information About Medications for Opioid Use Disorder
• FDA: Primary Care Providers Can Prescribe With Confidence
• SAMHSA TIP 63
• NIDA: Medications for Opioid Use Disorder
• CDC: Treatment of Opioid Use Disorder
• SAMHSA: Removal of the DATA-Waiver requirement
• SAMHSA: Methadone
• eCFR: 42 CFR 8.12(i), take-home medication criteria
• NIDA: Principles of Drug Addiction Treatment, Third Edition
• CDC: Reverse Opioid Overdose to Prevent Death
• FDA labeling via DailyMed: Vivitrol (naltrexone)
• FDA labeling via DailyMed: Suboxone (buprenorphine and naloxone)
• FDA labeling via DailyMed: Methadone

Sources checked September 7, 2026